Cybin (CYBN) Competitors $9.40 -0.07 (-0.74%) (As of 03:34 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CYBN vs. AVXL, IMNM, KURA, KROS, TYRA, ERAS, CRON, EOLS, DNTH, and RAPPShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include Anavex Life Sciences (AVXL), Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Erasca (ERAS), Cronos Group (CRON), Evolus (EOLS), Dianthus Therapeutics (DNTH), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Anavex Life Sciences Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Erasca Cronos Group Evolus Dianthus Therapeutics Rapport Therapeutics Anavex Life Sciences (NASDAQ:AVXL) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, community ranking, analyst recommendations, media sentiment, profitability, risk and earnings. Which has more risk and volatility, AVXL or CYBN? Anavex Life Sciences has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Do institutionals and insiders hold more shares of AVXL or CYBN? 31.5% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend AVXL or CYBN? Anavex Life Sciences presently has a consensus price target of $43.00, indicating a potential upside of 400.58%. Cybin has a consensus price target of $138.00, indicating a potential upside of 1,368.09%. Given Cybin's higher possible upside, analysts clearly believe Cybin is more favorable than Anavex Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AVXL or CYBN more profitable? Anavex Life Sciences' return on equity of -30.64% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets Anavex Life SciencesN/A -30.64% -28.23% Cybin N/A -52.17%-50.52% Does the MarketBeat Community believe in AVXL or CYBN? Anavex Life Sciences received 419 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 74.44% of users gave Anavex Life Sciences an outperform vote. CompanyUnderperformOutperformAnavex Life SciencesOutperform Votes43174.44% Underperform Votes14825.56% CybinOutperform Votes12100.00% Underperform VotesNo Votes Which has preferable valuation & earnings, AVXL or CYBN? Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnavex Life SciencesN/AN/A-$47.51M-$0.50-17.18CybinN/AN/A-$57.88M-$6.66-1.41 Does the media prefer AVXL or CYBN? In the previous week, Anavex Life Sciences had 4 more articles in the media than Cybin. MarketBeat recorded 4 mentions for Anavex Life Sciences and 0 mentions for Cybin. Anavex Life Sciences' average media sentiment score of 0.75 beat Cybin's score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Anavex Life Sciences Positive Cybin Neutral SummaryAnavex Life Sciences beats Cybin on 11 of the 16 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$187.93M$6.79B$5.10B$19.48BDividend YieldN/A3.06%4.83%3.51%P/E Ratio-1.4110.68133.9443.10Price / SalesN/A279.711,156.9017.54Price / CashN/A57.1640.5621.73Price / Book0.875.334.845.40Net Income-$57.88M$151.85M$118.62M$987.88M7 Day Performance-8.56%-5.51%13.62%-3.32%1 Month Performance-11.32%1.18%13.91%-0.39%1 Year PerformanceN/A15.17%33.64%15.14% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin1.8777 of 5 stars$9.40-0.7%$138.00+1,368.1%N/A$187.93MN/A-1.4150AVXLAnavex Life Sciences3.5728 of 5 stars$9.27+9.6%$43.00+363.9%+4.2%$786.10MN/A-18.5440IMNMImmunome2.6346 of 5 stars$12.47-0.9%$28.83+131.2%+59.4%$778.34M$10.13M-1.5540Short Interest ↓Positive NewsKURAKura Oncology4.529 of 5 stars$9.94+3.2%$29.38+195.5%-20.8%$772.93MN/A-4.08142KROSKeros Therapeutics3.0921 of 5 stars$18.80-0.2%$81.33+332.6%-44.6%$761.53M$651,000.00-3.61100Analyst DowngradeNews CoverageHigh Trading VolumeTYRATyra Biosciences2.1888 of 5 stars$14.93-0.1%$31.00+107.6%+12.7%$755.46MN/A-9.2820ERASErasca2.6129 of 5 stars$2.60+1.6%$5.90+126.9%+40.6%$735.09MN/A-3.08126Positive NewsGap UpCRONCronos Group2.3543 of 5 stars$1.92-0.4%$3.00+56.1%+1.0%$734.86M$87.24M-15.19356Short Interest ↓News CoveragePositive NewsEOLSEvolus3.9289 of 5 stars$11.53+0.2%$23.00+99.5%+18.5%$730.08M$202.09M-12.73170Positive NewsDNTHDianthus Therapeutics1.6778 of 5 stars$24.31+2.1%$46.43+91.0%+235.7%$719.58M$2.83M-9.5280Positive NewsRAPPRapport Therapeutics1.8607 of 5 stars$19.36+3.1%$35.00+80.8%N/A$708.19MN/A0.00N/APositive News Related Companies and Tools Related Companies AVXL Competitors IMNM Competitors KURA Competitors KROS Competitors TYRA Competitors ERAS Competitors CRON Competitors EOLS Competitors DNTH Competitors RAPP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CYBN) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYBN Stock Alerts